Skip to main content
Fig. 2 | Cancer Communications

Fig. 2

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Fig. 2

PFS following R–CVP and rituximab-maintenance therapy in the intent-to-treat population. Kaplan–Meier plot of PFS in patients with advanced MZL treated with rituximab-maintenance following first-line R–CVP therapy. MZL marginal zone lymphoma, PFS progression-free survival, R–CVP rituximab cyclophosphamide vincristine prednisolone

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us